echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kelun/and platinum jointly declare the second domestic paragraph of TSLP antibody

    Kelun/and platinum jointly declare the second domestic paragraph of TSLP antibody

    • Last Update: 2021-12-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 14, the official website of CDE showed that Hebo Medicine and Kelun Botai declared HBM9378 injection (ie SKB378)


    TSLP is one of the initiating factors of the inflammatory cascade.


    In April 2018, Hebo Pharma and Kelun Botai reached a global strategic cooperation to jointly research, develop and commercialize new fully human antibody drugs


    According to the Insight database, a total of 5 products with the same target are currently under research worldwide, of which 3 are developed by domestic companies


    Global R&D Progress of Targeting TSLP Monoclonal Antibody Drugs

    From: Insight database (http://db.


    From the perspective of foreign progress, Novartis’ CSJ117 and Amgen/AstraZeneca’s Tezepelumab are in the late stages of clinical trials respectively, and Tezepelumab has also initiated phase III clinical trials in China


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.